08:26 AM EDT, 06/26/2025 (MT Newswires) -- ZyVersa Therapeutics ( ZVSA ) said Thursday that the first clinical site for its phase 2a clinical study of VAR 200 in patients with diabetic kidney disease has been activated.

The company said the activated site, the Clinical Advancement Center in San Antonio, Texas, is ready to recruit patients for the study.

Shares of ZyVersa Therapeutics ( ZVSA ) were down 2.8% in recent premarket activity.